

# Jill P Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2794832/publications.pdf>

Version: 2024-02-01

44  
papers

1,278  
citations

361045

20  
h-index

360668

35  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1905  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Role of an anti-gastrin vaccine (PAS) alone and in combination with a PD-1 antibody on growth and metastases of gastric cancer.. Journal of Clinical Oncology, 2022, 40, 334-334.                                  | 0.8 | 0         |
| 2  | The CCK-B receptor: A novel target for therapy of hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 466-466.  | 0.8 | 0         |
| 3  | Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. International Journal of Molecular Sciences, 2022, 23, 1899.                            | 1.8 | 5         |
| 4  | Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment. Pharmaceutics, 2022, 14, 627.   | 2.0 | 1         |
| 5  | Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. Cancer Prevention Research, 2021, 14, 17-30.   | 0.7 | 13        |
| 6  | Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model. Cancer Prevention Research, 2021, 14, 933-944.   | 0.7 | 1         |
| 7  | A 584Åbp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. American Journal of Human Genetics, 2021, 108, 1852-1865.  | 2.6 | 15        |
| 8  | Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. Cancers, 2021, 13, 4949.                                       | 1.7 | 7         |
| 9  | Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas. Biomolecules, 2021, 11, 1766.  | 1.8 | 6         |
| 10 | Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer. Frontiers in Oncology, 2021, 11, 788875.   | 1.3 | 6         |
| 11 | TGFÎ² Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFÎ² Induced EMT in PDAC. Cancers, 2021, 13, 6204.  | 1.7 | 8         |
| 12 | Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis. Digestive Diseases and Sciences, 2020, 65, 1376-1384.   | 1.1 | 11        |
| 13 | A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2020, 65, 189-203.  | 1.1 | 15        |
| 14 | A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.                                      | 3.0 | 59        |
| 15 | Role of the Î²-Opioid Receptor in 2 Murine Models of Colitis. Comparative Medicine, 2020, 70, 25-34.   | 0.4 | 1         |
| 16 | Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases. American Journal of Physiology - Renal Physiology, 2019, 317, G682-G693.  | 1.6 | 9         |
| 17 | ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression. Cancer Immunology, Immunotherapy, 2019, 68, 2029-2039. | 2.0 | 19        |
| 18 | Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunology, Immunotherapy, 2019, 68, 1635-1648.                         | 2.0 | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis. <i>Pancreas</i> , 2019, 48, 894-903.  | 0.5 | 8         |
| 20 | Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.  | 5.8 | 188       |
| 21 | Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 17-32.   | 2.3 | 17        |
| 22 | Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 195-207.                                       | 2.0 | 25        |
| 23 | Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G699-G712.                             | 1.6 | 31        |
| 24 | Gastrin and Gastric Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 4, 75-83.  | 2.3 | 59        |
| 25 | Effect of liver histopathology on islet cell engraftment in the model mimicking autologous islet cell transplantation. <i>Islets</i> , 2017, 9, 140-149.   | 0.9 | 13        |
| 26 | Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 2313-2324. | 1.7 | 11        |
| 27 | A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 23-35.  | 2.0 | 34        |
| 28 | The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. <i>International Journal of Biological Sciences</i> , 2016, 12, 283-291.  | 2.6 | 53        |
| 29 | Distribution of Cholecystokinin-B Receptor Genotype Between Patients With Pancreatic Cancer and Controls and Its Impact on Survival. <i>Pancreas</i> , 2015, 44, 236-242.  | 0.5 | 10        |
| 30 | Cholecystokinin Receptor Antagonist Halts Progression of Pancreatic Cancer Precursor Lesions and Fibrosis in Mice. <i>Pancreas</i> , 2014, 43, 1050-1059.  | 0.5 | 36        |
| 31 | Cholecystokinin and pancreatic cancer: the chicken or the egg?. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G91-G101.  | 1.6 | 52        |
| 32 | Cholecystokinin Mediates Progression and Metastasis of Pancreatic Cancer Associated with Dietary Fat. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1180-1191.  | 1.1 | 30        |
| 33 | Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 339-345.   | 1.1 | 44        |
| 34 | Role of endogenous cholecystokinin on growth of human pancreatic cancer. <i>International Journal of Oncology</i> , 2011, 38, 593-601.   | 1.4 | 23        |
| 35 | Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn's Disease: A Randomized Placebo-Controlled Trial. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2088-2097.   | 1.1 | 100       |
| 36 | Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. <i>Open Access Journal of Clinical Trials</i> , 2010, 2010, 37.   | 1.5 | 26        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Growth of Human Pancreatic Cancer Is Inhibited by Down-Regulation of Gastrin Gene Expression. <i>Pancreas</i> , 2009, 38, e151-e161.   | 0.5 | 30        |
| 38 | Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, 820-828.   | 0.2 | 115       |
| 39 | Amantadine Therapy for Chronic Hepatitis C: A Dose Escalation Study. <i>American Journal of Gastroenterology</i> , 2004, 99, 1099-1104.  | 0.2 | 16        |
| 40 | Functional significance of gastrin gene expression in human cancer cells. <i>Regulatory Peptides</i> , 2004, 117, 167-173.   | 1.9 | 16        |
| 41 | The Functional Significance of the Cholecystokinin-C (CCK-C) Receptor in Human Pancreatic Cancer. <i>Pancreas</i> , 2004, 29, 271-277.   | 0.5 | 25        |
| 42 | Treatment of advanced pancreatic cancer with opioid growth factor: phase I. <i>Anti-Cancer Drugs</i> , 2004, 15, 203-209.  | 0.7 | 53        |
| 43 | Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. <i>International Journal of Molecular Medicine</i> , 2002, 10, 689-94.   | 1.8 | 50        |
| 44 | Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 267-274. | 1.1 | 24        |